Details of the Drug Reposition

General Information of This Drug (ID: DMOZAMN)

Drug Name
TAK-935   DMOZAMN
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Dravet syndrome DISJF7LY 8A61.11 Phase 2 [1]
LennoxGastaut syndrome DISOTGO5 8A62.1 Phase 2 [1]
Tuberous sclerosis DISEMUGZ LD2D.2 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glutamate excitotoxity DISAIUO3 5C73 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02201056) Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935. U.S. National Institutes of Health.